Background In the United States, millions of patients are living with HIV and Hepatitis C (0.44% and 1.5%) and many are currently undiagnosed. Since highly effective treatments are now available, early identification of these patients is extremely important to achieve improved clinical outcomes. Prior data and trauma-associated risk factors suggest a higher prevalence of both diseases in the trauma population. We hypothesized that a screening program could be successfully initiated amongst trauma activation patients and that a referral and linkage-to-care program could be developed. Methods Hepatitis C and HIV screening tests were added to standard trauma activation lab orders at an academic Level 1 Trauma Center. Confirmatory viral load was sent when indicated. Patients with positive results were educated about their disease and referred to disease-specific follow-up. Data was collected prospectively from January 1, 2016 until June 30, 2017. Total and new diagnosis, referral rates, and linkage-to-care rates were analyzed. Results 1898 patients arrived as trauma activations. 1217 patients (64.1%) were screened (Level A = 75.6%, Level B = 60.2%). 7% of screened patients were initially positive and 5.5% were confirmed positive. Rates of both HIV (1.1%) and Hepatitis C (4.4%) were almost triple the national average. Overall, 3.3% screened positive for a new diagnosis. For Hepatitis C, the rate of new diagnosis was twice the national average (3%). Over 85% of all cases were referred for follow-up and the combined linkage-to-care rate was 43.3%. Conclusions The majority of patients were screened and referred for follow-up indicating successful implementation of our trauma screening program. Routine screening of trauma patients should be considered to increase diagnosis rate, increase linkage-to-care rates, and decrease disease transmission. These screening efforts would help bridge the health care gap that exists in the trauma population due to lower insurance rates and limited access to primary care. Level of Evidence Level III Study Type Prospective Intervention Correspondence: Alicia Privette, MD, FACS, Medical University of South Carolina, 96 Jonathan Lucas Street, MSC 613/CSB 420, Charleston, SC 29425. Tel: (843) 792-3780; Fax: (843) 792-5906 Address for reprints: Same as correspondence Conflict of Interest: No conflict of interest exists for any of the authors Meeting Presentation: 48th Annual Meeting of the Western Trauma Association, February 25 to March 2, 2018 in Whistler, Canada Funding disclosure: The authors have no funding for this project to disclose © 2018 Lippincott Williams & Wilkins, Inc.
from Emergency Medicine via xlomafota13 on Inoreader https://ift.tt/2LLKCoe
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Ravulizumab (ravulizumab-cwvz; ULTOMIRIS™), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Ph...
-
http://bit.ly/2TO0eLw
-
Abstract Chronic low-grade inflammation is now widely accepted as one of the most important contributors to metabolic disorders. Glycoprot...
-
Abstract Objective Long-acting synthetic somatostatin analogues (SSA) are an essential part of the treatment of neuroendocrine neoplasms...
-
Training in teamwork behaviour improves technical resuscitation performance. However, its effect on patient outcome is less clear, partly be...
-
Medicine by Alexandros G. Sfakianakis BioMed Research International BioMed Research InternationalTanshinone IIA Alleviates CCL2-Induced Le...
-
Abstract Chronic venous disease (CVD) is both prevalent and unavoidable in many people as a result of persistent or unalterable risk facto...
-
Abstract Purpose Reports of acute treatment-related dysphagia and toxicities for patients with parotid tumours or cutaneous head and nec...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου